Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 5/20 | 0.38 |
| ▸ | YAP1 | P46937 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 2/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3072475 | 0.98 | UTS2R (0.38) | UTS2RYAP1PDE4BRENUSP30 | |
| SCHEMBL3073604 | 0.91 | UTS2R (0.39) | UTS2RPDE4BRENCYP3A4CHRM1 | |
| SCHEMBL3061303 | 0.90 | UTS2R (0.41) | UTS2RPDE4BRENCYP3A4CHRM1 | |
| SCHEMBL3081046 | 0.90 | PDE4B (0.38) | UTS2RPDE4BRENCYP3A4CHRM1 | |
| SCHEMBL3079565 | 0.90 | PDE4B (0.38) | UTS2RPDE4BRENCYP3A4CHRM1 | |
| SCHEMBL3083196 | 0.89 | REN (0.43) | UTS2RYAP1PDE4BRENCYP3A4 | |
| SCHEMBL3077558 | 0.89 | UTS2R (0.42) | UTS2RPDE4BRENCYP3A4CHRM1 | |
| SCHEMBL3074050 | 0.89 | REN (0.40) | UTS2RPDE4BRENCYP3A4 | |
| SCHEMBL3069812 | 0.88 | UTS2R (0.43) | UTS2RPDE4BRENCYP3A4CHRM1 | |
| SCHEMBL3081461 | 0.88 | UTS2R (0.40) | UTS2RYAP1PDE4BRENCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | UTS2R 514/4885YAP1 916/4885PDE4B 312/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | UTS2R 514/4885YAP1 916/4885PDE4B 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.